Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455250 | 0.83 | KDM4E (0.31) | KDM4EMAPKAPK2SIGMAR1 | |
| SCHEMBL275946 | 0.71 | LMNA (0.33) | KDM4EMAPKAPK2HTTLMNACYP1A2 | |
| SCHEMBL5657919 | 0.69 | CHUK (0.36) | KDM4EHTTLMNA | |
| SCHEMBL25010 | 0.69 | KDM4E (0.37) | KDM4EMAPKAPK2HTTLMNACYP1A2 | |
| SCHEMBL130352 | 0.69 | CYP2A6 (0.33) | — | |
| SCHEMBL18987 | 0.68 | CYP1A2 (0.39) | KDM4EMAPKAPK2HTTLMNACYP1A2 | |
| SCHEMBL5660013 | 0.68 | CHUK (0.35) | — | |
| SCHEMBL5926099 | 0.68 | IMPDH2 (0.33) | KDM4ECYP1A2 | |
| SCHEMBL17511868 | 0.67 | KDM4E (0.38) | KDM4EMAPKAPK2HTTLMNACYP1A2 | |
| SCHEMBL449142 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115650850-A | Nano-oxide surface modifier based on fatty acid and preparation method and application thereof | 武汉轻工大学 | 2023-01-31 | — | — | CN | claimed |
| CN-115650850-A | Nano-oxide surface modifier based on fatty acid and preparation method and application thereof | 武汉轻工大学 | 2023-01-31 | — | — | CN | disclosed |
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-08-06 | — | — | US | disclosed |
| US-9029381-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2015-05-12 | — | — | US | disclosed |
| EP-2805937-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2014-11-26 | — | — | EP | disclosed |
| EP-2253615-B1 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2014-07-09 | — | — | EP | disclosed |
| EP-2195293-B1 | CYCLOPTOPYL AMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-8063215-B2 | Cyclopropyl amide derivatives | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| EP-2253615-A1 | Cyclopropyl amide derivatives | AstraZeneca AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2195293-A2 | CYCLOPTOPYL AMIDE DERIVATIVES | AstraZeneca AB (SE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| WO-2009024823-A2 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |
| US-6166210-A | Perylene imide monocarboxylic acids | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-12-26 | — | — | US | disclosed |
| EP-1053228-A1 | PERYLENE IMIDE MONOCARBOXYLIC ACIDS AS COLORANTS | Ciba SC Holding AG (CH) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999031069-A1 | PERYLENE IMIDE MONOCARBOXYLIC ACIDS AS COLORANTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216861-A1 | CYCLOPROPYL AMIDE DERIVATIVES | HRH4, HRH2, HRH3 | KDM4E 2084/4885MAPKAPK2 2636/4885HTT 1689/4885 |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | KDM4E 1779/4885MAPKAPK2 1959/4885HTT 1161/4885 |
| US-20090076020-A1 | Cyclopropyl Amide Derivatives 978 | HRH4, HRH2, HRH3 | KDM4E 1721/4885MAPKAPK2 2405/4885HTT 1570/4885 |
| US-20120065193-A1 | Cyclopropyl Amide Derivatives '978 | HRH2, HRH4, HRH3 | KDM4E 1573/4885MAPKAPK2 2768/4885HTT 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.